DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ergonovine is an investigational drug.
There have been 10 clinical trials for Ergonovine. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2019.
The most common disease conditions in clinical trials are Hemorrhage, Postpartum Hemorrhage, and Uterine Inertia. The leading clinical trial sponsors are Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Kosin University Gospel Hospital, and Swiss Group for Clinical Cancer Research.
There are four hundred and sixty-eight US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for Ergonovine
|Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients||Nicole M. Masse||Phase 4|
|Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina||Kosin University Gospel Hospital||Phase 4|
|Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial||Brigham and Women's Hospital||Phase 4|
Top disease conditions for Ergonovine
Top clinical trial sponsors for Ergonovine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ergonovine||See Pricing||Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof||Gel-Del Technologies, Inc. (St. Paul, MN)||See Pricing|
|Ergonovine||See Pricing||Methods and systems for the delivery of a therapeutic agent||UNIVERSITY OF ICELAND (Reykjavik, IS)||See Pricing|
|Ergonovine||See Pricing||Pyrimidines as sodium channel blockers||Purdue Pharma L.P. (Stamford, CT)||See Pricing|
|Ergonovine||See Pricing||Treatment of sexual dysfunction||Rejoy (Irvine, CA)||See Pricing|
|Ergonovine||See Pricing||Compositions and methods for prophylaxis and treatment of addictions||Omeros Corporation (Seattle, WA)||See Pricing|
|Ergonovine||See Pricing||Crystallization method and bioavailability||GRUNENTHAL GMBH (DE)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ergonovine||World Intellectual Property Organization (WIPO)||2010057177||2028-11-17||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|